{
    "clinical_study": {
        "@rank": "82494", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate clinical safety issues pertaining to flupenthixol,\n      to cocaine, and to their interaction, and to determine how pretreatment with flupenthixol\n      modifies the subjective as well as physiological effects of cocaine. Taken together, these\n      relatively D-1 selective agents can help determine the extent to which DA-1 binding affects\n      the reinforcing effects of stimulants."
        }, 
        "brief_title": "Infusion Laboratory: Protocol 5 (Flupenthixol) - 14", 
        "condition": "Cocaine-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the\n        study and sign informed consent.\n\n        Exclusion Criteria:\n\n        Psychiatric disorder that requires medication therapy. History of seizures. Pregnant\n        and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics.\n        Acute hepatitis. Other medical condtions that deem participation to be unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000349", 
            "org_study_id": "NIDA-3-0010-14", 
            "secondary_id": "Y01-3-0010-14"
        }, 
        "intervention": {
            "intervention_name": "Flupenthixol", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Flupenthixol", 
                "Flupenthixol decanoate"
            ]
        }, 
        "lastchanged_date": "August 16, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90025"
                }, 
                "name": "Friends Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Infusion Laboratory: Protocol 5 (Flupenthixol)", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Walter Ling, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "primary_outcome": [
            {
                "measure": "Degree of drug craving"
            }, 
            {
                "measure": "History, incidence and amount of drug use"
            }, 
            {
                "measure": "Type and severity of stimulant withdrawal symptoms"
            }, 
            {
                "measure": "Characterization of study population"
            }, 
            {
                "measure": "Population incidence of symptoms of depression, po"
            }, 
            {
                "measure": "Frequency and intensity of drug use and sexual beh"
            }, 
            {
                "measure": "Evidence of change in neurophysiology and brain ac"
            }, 
            {
                "measure": "Evidence of change in subjective responses to coca"
            }, 
            {
                "measure": "Clinical physiological response to cocaine challen"
            }, 
            {
                "measure": "Degree to which study medication influences change"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000349"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2002"
    }, 
    "geocoordinates": {
        "Friends Research Institute": "34.052 -118.244"
    }
}